BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Alpibectir readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Alpibectir\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05807399-11202@assetmemo.bio
DTSTAMP:20261121T004024Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Alpibectir: Phase 2 readout est. (NCT05807399)
DESCRIPTION:Alpibectir\, phase 2\, Tuberculosis.\nStudy: PanACEA - STEP2C -
 01\nEstimated primary completion: 31 October 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/alpibectir#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05807399
URL:https://assetmemo.bio/drug/alpibectir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07350174-11202@assetmemo.bio
DTSTAMP:20261121T004024Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Alpibectir: Phase 2 readout est. (NCT07350174)
DESCRIPTION:Alpibectir\, phase 2\, Tuberculosis.\nStudy: Phase 2a Trial of 
 Alpibectir Plus Ethionamide for Tuberculosis Meningitis\nEstimated primary
  completion: 30 March 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/alpibectir#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07350174
URL:https://assetmemo.bio/drug/alpibectir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
